

# CORPORATE EVENTS

**MEMO # 09-383**

**DATE: 09/02/09**

---

**ACTION:**

On August 31, 2009, Puma Acquisition Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company completed its subsequent tender offer for Medarex, Inc. ("MEDX") Common Shares. The merger was subsequently consummated on September 1, 2009. As a result, each existing MEDX Common Share will be converted into the right to receive \$16.00 net cash per share.

This corporate event will be coordinated with the Options Clearing Corporation.

**CATEGORY:**

Cash Settlement

**EQUITY SYMBOL:**

Medarex, Inc. ("MEDX")

**ONECHICAGO SYMBOL:**

MEDX1C will be delisted

**CME FUTURES SYMBOL:**

**MDX** will be delisted

**EFFECTIVE DATE:**

**September 3, 2009**

**MULTIPLIER:**

100 (e.g., 1.00 equals \$100.00)

**NEW DELIVERABLE PER CONTRACT:**

\$1,600

**APPLICABLE CONTRACT MONTHS:**

September, October, December 2009 and March 210

**SETTLEMENT PRICES AND POSITIONS:**

The final settlement price shall be \$16.00.

**NOTES:**

The forecasted effect of the upcoming corporate event on each clearing firm's positions can be viewed in infopac in the Corporate Event Initial Forecast Report (ONE712), the Corporate Event Final Forecast Report (ONE713), and the Corporate Event Forecast Audit Report (CPDBU710).

The details after the corporate event has been applied can be viewed in the Corporate Event Activity Report (ONE711).

If you have any questions regarding the information provided in the document, please call CME Clearing Risk Management hotline at (312) 648-3888.